logo

For the Inventor, By the Inventor

Wilmington, DE, United States of America

Alexander L Johnson

This inventor holds 9 USPTO granted patents. Top assignee: E.i. Dupont De Nemours and Company. Active years: 1976-1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexander L Johnson. Retrieved from https://idiyas.com/inventor/alexander-l-johnson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 1.4

ph-index = 5

Forward Citations = 81(Granted Patents)


Company Filing History:

goldMedal9 out of 16,339 
 
E.i. Dupont De Nemours and Company
 patents

Years Active: 1976-1989

Loading Chart...
9 patents (USPTO):Explore Patents
1. 4868181 - 1,4-dihydropyridine derivatives with calcium agonist and alpha.sub.1 (1989-09-19),
2. 4439364 - Process for preparing antihypertensive 1-substituted cyclic (1984-03-27),
3. 4296110 - Antihypertensive I-substituted cyclic lactam-2-carboxylic acids (1981-10-20),
4. 4147860 - Process for preparing nitroaromatic glycosides (1979-04-03),
5. 4145527 - Nitro aromatic glycosides (1979-03-20),
6. 4069035 - 1-(2-Carboxyaryl)-3-aryl-1,2,4-triazoles and use as herbicides (1978-01-17),
7. 4055409 - Pyrazole plant growth regulants (1977-10-25),
8. 4038285 - 1-(2-Carboxyaryl)-4-arylimidazoles and (1977-07-26),
9. 3948937 - Pyrazole plant growth regulants (1976-04-06),

Title: The Innovative Contributions of Alexander L Johnson

Introduction

Alexander L Johnson is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications. With a total of 9 patents to his name, Johnson's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Among his latest patents, Johnson has developed 1,4-dihydropyridine derivatives that act as calcium agonists and alpha.sub.1 antagonists. These innovative compounds are particularly useful in treating congestive heart failure. The derivatives are characterized by a specific formula, wherein Ar, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are defined in the specification. Additionally, he has worked on a process for preparing antihypertensive 1-substituted cyclic lactam-2-carboxylic acids and their derivatives. This process involves reacting an ester with a suitable derivative, showcasing his expertise in chemical synthesis.

Career Highlights

Johnson is currently employed at E.I. du Pont de Nemours and Company, a leading organization in the field of science and technology. His role at the company allows him to further his research and development efforts, contributing to advancements in pharmaceutical innovations.

Collaborations

Throughout his career, Johnson has collaborated with esteemed colleagues such as Philip B Sweetser and Ruth Richmond Wexler. These partnerships have likely enhanced the scope and impact of his research, fostering a collaborative environment for innovation.

Conclusion

In summary, Alexander L Johnson is a distinguished inventor whose work in pharmaceuticals has led to the development of important therapeutic compounds. His contributions, particularly in the area of congestive heart failure treatment, highlight the significance of innovation in improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…